HMGB1 peptide engineering splits two immune functions into separate constructs
A short engineered fragment of HMGB1 has been pared down to two compact peptides with different jobs: one blocks NETosis, and the other disrupts biofilms. The separation is biologically important because the same parent molecule had carried both activities, creating a risk that a therapy aimed at neutrophil extracellular traps might also interfere with microbial communities that the host still needs to control.
Investigators started from mB Box-97, a 97-amino-acid B-box-derived peptide previously modified with a C106S substitution to temper HMGB1’s proinflammatory profile while preserving anti-biofilm activity. In the new work, shorter variants built around Helix 1 of the B-box were tested with and without the A Box–B Box linker, and with point mutations at DNA-contact residues. The result was a sharp functional split. A 42-amino-acid linker-plus-Helix 1 peptide retained both anti-NETotic and anti-biofilm activity, while a 29-amino-acid Helix 1-only peptide kept the biofilm effect but lost NET inhibition.
The biology behind the split is straightforward and clinically relevant. NETosis depends on a signaling cascade centered on protein kinase C activation, downstream NADPH oxidase activity, and the burst of reactive oxygen species that helps drive chromatin release. By interfering with PKC, the linker-containing peptide dampened that cascade and reduced NET formation. Biofilm disruption, by contrast, depended on DNA binding. Once the DNA-binding residues were altered, the peptide no longer disrupted biofilm structure but still retained its ability to suppress NETosis.
PKC inhibition tracks with NET suppression, while DNA binding tracks with biofilm activity
Human neutrophils provided the readout for the anti-NETotic arm of the work. The peptides were tested in the setting of phorbol 12-myristate 13-acetate stimulation, a canonical PKC activator used to drive NET formation. In those assays, the linker-containing peptides with C106S significantly inhibited NETosis. The mechanism aligned with a deeper biochemical sequence: peptide binding to PKC, inhibition of PKC activity, reduced activation of NADPH oxidase, and lower reactive oxygen species generation. In practical terms, the construct interrupted the upstream switch that normally pushes neutrophils toward extracellular trap release.
One sentence captures the key split cleanly: removing the linker abolished anti-NETotic activity.
A different pattern emerged when the peptides were modified at established DNA-contact residues within HMGB1’s B-box. Substitutions at R97 and F103 were designed to weaken DNA-binding and intercalation without dismantling the rest of the peptide backbone. Once those mutations were introduced into the linker–Helix 1 construct, anti-biofilm activity disappeared, but the anti-NETotic effect remained. The interpretation is direct: DNA binding is required for biofilm disruption, but it is not required for PKC-dependent NET suppression.
This matters because biofilms and NETs often sit on opposite sides of the same host-pathogen tug-of-war. Biofilms protect bacteria from phagocytosis, antimicrobials, and immune clearance. NETs can trap microbes, but excessive or misdirected NET release also contributes to inflammation and tissue injury. A peptide that selectively suppresses NETosis without stripping away anti-biofilm function could, in theory, lower inflammatory damage while preserving one of HMGB1’s antibacterial effects. The converse construct, which preserves anti-biofilm function but lacks NET inhibition, may have utility where matrix disruption is desired without altering neutrophil signaling.
Compact peptide size strengthens the case for translational use, but the biology stays context dependent
The final constructs are small enough to matter from a development standpoint. The 42-amino-acid linker–Helix 1 peptide and the 29-amino-acid Helix 1-only peptide are readily synthesizable, a practical advantage over larger recombinant proteins. Smaller molecules are typically easier to manufacture, characterize, and modify for future formulation work. Here, size reduction did not come at the expense of functional precision; instead, it clarified which structural elements carried which immune activities.
The study also keeps PKC in the frame as a mechanistic target for NETosis inhibition. Because PKC sits upstream of NADPH oxidase and oxidative burst, it represents a plausible point of control for disorders in which NET formation is excessive. That could be relevant in inflammatory diseases where NETs drive pathology, including settings where extracellular DNA, proteases, and oxidant stress amplify tissue injury. At the same time, the work warns against assuming that all NET-targeting strategies are interchangeable. A therapy that suppresses neutrophil traps but also erodes biofilm defense could create a different clinical problem in patients with chronic or device-associated bacterial infection.
Human neutrophils, not a surrogate cell line, anchored the study’s primary mechanistic conclusions, and pathogenic bacteria were used to test biofilm activity. The bacterial panel included non-typeable Haemophilus influenzae, methicillin-resistant Staphylococcus aureus, Pseudomonas aeruginosa, Klebsiella pneumoniae, and Streptococcus pneumoniae. Those organisms are relevant to persistent infection biology because several are well known for forming matrix-protected communities that resist standard treatment. The peptide effects were assessed against that backdrop, strengthening the argument that the observed biofilm disruption was not organism-specific noise but a broader matrix-directed function tied to DNA binding.
A final caution is built into the dataset itself. The work is mechanistic and preclinical, and it does not establish therapeutic performance in animals or people. The next questions are narrow and concrete: how these peptides behave in vivo, whether their activity holds in complex inflammatory microenvironments, and how selectively they act when biofilms and NETs coexist in the same tissue. Those questions will determine whether the structural split discovered here can be translated into a usable anti-inflammatory or anti-infective strategy.